Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

Core Insights - Dianthus Therapeutics has made a GO decision in the Phase 3 CAPTIVATE trial for claseprubart, targeting Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with an early achievement of 20 confirmed responders from less than 40 participants [1][5][6] - The company is set to initiate a Phase 3 trial for claseprubart in generalized Myasthenia Gravis (gMG) in mid-2026, with top-line results expected in the second half of 2028 [1][6][14] - Financial results for the year ending December 31, 2025, show a net loss of $162.3 million, with cash reserves of $514.4 million projected to sustain operations into 2028 [1][13][10] Clinical Development - Claseprubart is a monoclonal antibody designed to selectively inhibit the C1s protein, with a self-administered subcutaneous injection option [3][14] - The Phase 2 MoMeNtum trial for claseprubart in Multifocal Motor Neuropathy (MMN) is ongoing, with top-line results anticipated in the second half of 2026 [1][8] - DNTH212, another investigational product, is in a Phase 1 study with results expected in the second half of 2026 [1][9] Financial Overview - R&D expenses for 2025 were $145.6 million, up from $83.1 million in 2024, primarily due to increased clinical costs and headcount [13] - General and administrative expenses rose to $34.3 million in 2025 from $25.0 million in 2024, reflecting higher staffing costs [13] - The company reported a net loss per share of $4.20 for 2025, compared to $2.55 in 2024 [13][27]